nodes	percent_of_prediction	percent_of_DWPC	metapath
Diphenhydramine—Neuropathy peripheral—Altretamine—ovarian cancer	0.0209	0.0263	CcSEcCtD
Diphenhydramine—Neuritis—Chlorambucil—ovarian cancer	0.0182	0.0228	CcSEcCtD
Diphenhydramine—Vertigo—Altretamine—ovarian cancer	0.015	0.0188	CcSEcCtD
Diphenhydramine—Convulsion—Altretamine—ovarian cancer	0.0145	0.0182	CcSEcCtD
Diphenhydramine—Thrombocytopenia—Altretamine—ovarian cancer	0.0133	0.0168	CcSEcCtD
Diphenhydramine—Anorexia—Altretamine—ovarian cancer	0.013	0.0163	CcSEcCtD
Diphenhydramine—Chest tightness—Docetaxel—ovarian cancer	0.0126	0.0158	CcSEcCtD
Diphenhydramine—Decreased appetite—Altretamine—ovarian cancer	0.0118	0.0149	CcSEcCtD
Diphenhydramine—Fatigue—Altretamine—ovarian cancer	0.0117	0.0148	CcSEcCtD
Diphenhydramine—Haemolytic anaemia—Chlorambucil—ovarian cancer	0.0109	0.0137	CcSEcCtD
Diphenhydramine—Asthenia—Altretamine—ovarian cancer	0.00977	0.0123	CcSEcCtD
Diphenhydramine—Haemolytic anaemia—Melphalan—ovarian cancer	0.00951	0.0119	CcSEcCtD
Diphenhydramine—Neuritis—Paclitaxel—ovarian cancer	0.00931	0.0117	CcSEcCtD
Diphenhydramine—Dizziness—Altretamine—ovarian cancer	0.00901	0.0113	CcSEcCtD
Diphenhydramine—PTGS1—oviduct—ovarian cancer	0.00869	0.097	CbGeAlD
Diphenhydramine—Vomiting—Altretamine—ovarian cancer	0.00866	0.0109	CcSEcCtD
Diphenhydramine—Extrasystoles—Paclitaxel—ovarian cancer	0.00826	0.0104	CcSEcCtD
Diphenhydramine—Nausea—Altretamine—ovarian cancer	0.00809	0.0102	CcSEcCtD
Diphenhydramine—Neuritis—Docetaxel—ovarian cancer	0.00789	0.00991	CcSEcCtD
Diphenhydramine—Chest discomfort—Paclitaxel—ovarian cancer	0.00786	0.00987	CcSEcCtD
Diphenhydramine—Neuropathy peripheral—Chlorambucil—ovarian cancer	0.00744	0.00935	CcSEcCtD
Diphenhydramine—CYP2C18—uterine cervix—ovarian cancer	0.00719	0.0803	CbGeAlD
Diphenhydramine—Wheezing—Paclitaxel—ovarian cancer	0.00675	0.00848	CcSEcCtD
Diphenhydramine—Chest discomfort—Docetaxel—ovarian cancer	0.00666	0.00836	CcSEcCtD
Diphenhydramine—Neuropathy peripheral—Topotecan—ovarian cancer	0.00662	0.00832	CcSEcCtD
Diphenhydramine—Neuropathy peripheral—Melphalan—ovarian cancer	0.00649	0.00815	CcSEcCtD
Diphenhydramine—Neuropathy peripheral—Vinorelbine—ovarian cancer	0.00567	0.00712	CcSEcCtD
Diphenhydramine—Tremor—Chlorambucil—ovarian cancer	0.00556	0.00698	CcSEcCtD
Diphenhydramine—Nasal congestion—Paclitaxel—ovarian cancer	0.00554	0.00696	CcSEcCtD
Diphenhydramine—Agitation—Chlorambucil—ovarian cancer	0.00545	0.00685	CcSEcCtD
Diphenhydramine—Chills—Topotecan—ovarian cancer	0.00544	0.00684	CcSEcCtD
Diphenhydramine—Agranulocytosis—Vinorelbine—ovarian cancer	0.00539	0.00678	CcSEcCtD
Diphenhydramine—Neuritis—Epirubicin—ovarian cancer	0.00532	0.00669	CcSEcCtD
Diphenhydramine—Convulsion—Chlorambucil—ovarian cancer	0.00514	0.00646	CcSEcCtD
Diphenhydramine—Neuritis—Doxorubicin—ovarian cancer	0.00493	0.00619	CcSEcCtD
Diphenhydramine—Confusional state—Chlorambucil—ovarian cancer	0.00488	0.00613	CcSEcCtD
Diphenhydramine—CYP2C18—vagina—ovarian cancer	0.00488	0.0544	CbGeAlD
Diphenhydramine—Thrombocytopenia—Chlorambucil—ovarian cancer	0.00474	0.00596	CcSEcCtD
Diphenhydramine—Anorexia—Chlorambucil—ovarian cancer	0.00461	0.0058	CcSEcCtD
Diphenhydramine—Convulsion—Melphalan—ovarian cancer	0.00448	0.00563	CcSEcCtD
Diphenhydramine—Dyspepsia—Chlorambucil—ovarian cancer	0.00426	0.00535	CcSEcCtD
Diphenhydramine—Sweating increased—Paclitaxel—ovarian cancer	0.00425	0.00534	CcSEcCtD
Diphenhydramine—Thrombocytopenia—Topotecan—ovarian cancer	0.00422	0.0053	CcSEcCtD
Diphenhydramine—Decreased appetite—Chlorambucil—ovarian cancer	0.00421	0.00529	CcSEcCtD
Diphenhydramine—Fatigue—Chlorambucil—ovarian cancer	0.00417	0.00524	CcSEcCtD
Diphenhydramine—Hyperhidrosis—Topotecan—ovarian cancer	0.00417	0.00523	CcSEcCtD
Diphenhydramine—Thrombocytopenia—Melphalan—ovarian cancer	0.00413	0.00519	CcSEcCtD
Diphenhydramine—Tachycardia—Melphalan—ovarian cancer	0.00412	0.00517	CcSEcCtD
Diphenhydramine—Anorexia—Topotecan—ovarian cancer	0.00411	0.00516	CcSEcCtD
Diphenhydramine—Dysuria—Paclitaxel—ovarian cancer	0.00408	0.00512	CcSEcCtD
Diphenhydramine—Vertigo—Vinorelbine—ovarian cancer	0.00406	0.0051	CcSEcCtD
Diphenhydramine—Pollakiuria—Paclitaxel—ovarian cancer	0.00403	0.00506	CcSEcCtD
Diphenhydramine—Anorexia—Melphalan—ovarian cancer	0.00402	0.00505	CcSEcCtD
Diphenhydramine—Palpitations—Vinorelbine—ovarian cancer	0.00399	0.00502	CcSEcCtD
Diphenhydramine—Feeling abnormal—Chlorambucil—ovarian cancer	0.00399	0.00501	CcSEcCtD
Diphenhydramine—Photosensitivity reaction—Paclitaxel—ovarian cancer	0.00398	0.005	CcSEcCtD
Diphenhydramine—Hypotension—Melphalan—ovarian cancer	0.00394	0.00495	CcSEcCtD
Diphenhydramine—Paraesthesia—Topotecan—ovarian cancer	0.00387	0.00486	CcSEcCtD
Diphenhydramine—Urticaria—Chlorambucil—ovarian cancer	0.00385	0.00483	CcSEcCtD
Diphenhydramine—Neuropathy peripheral—Paclitaxel—ovarian cancer	0.00381	0.00479	CcSEcCtD
Diphenhydramine—Dyspepsia—Topotecan—ovarian cancer	0.00379	0.00477	CcSEcCtD
Diphenhydramine—Paraesthesia—Melphalan—ovarian cancer	0.00379	0.00476	CcSEcCtD
Diphenhydramine—Decreased appetite—Topotecan—ovarian cancer	0.00375	0.00471	CcSEcCtD
Diphenhydramine—Fatigue—Topotecan—ovarian cancer	0.00372	0.00467	CcSEcCtD
Diphenhydramine—Dyspepsia—Melphalan—ovarian cancer	0.00371	0.00467	CcSEcCtD
Diphenhydramine—Constipation—Topotecan—ovarian cancer	0.00369	0.00463	CcSEcCtD
Diphenhydramine—Decreased appetite—Melphalan—ovarian cancer	0.00367	0.00461	CcSEcCtD
Diphenhydramine—Fatigue—Melphalan—ovarian cancer	0.00364	0.00457	CcSEcCtD
Diphenhydramine—Thrombocytopenia—Vinorelbine—ovarian cancer	0.00361	0.00453	CcSEcCtD
Diphenhydramine—Tachycardia—Vinorelbine—ovarian cancer	0.0036	0.00452	CcSEcCtD
Diphenhydramine—Feeling abnormal—Topotecan—ovarian cancer	0.00355	0.00446	CcSEcCtD
Diphenhydramine—Toremifene—ESR1—ovarian cancer	0.00355	0.166	CrCbGaD
Diphenhydramine—SLC22A5—myometrium—ovarian cancer	0.00354	0.0395	CbGeAlD
Diphenhydramine—Anorexia—Vinorelbine—ovarian cancer	0.00351	0.00442	CcSEcCtD
Diphenhydramine—Asthenia—Chlorambucil—ovarian cancer	0.00347	0.00436	CcSEcCtD
Diphenhydramine—Hypotension—Vinorelbine—ovarian cancer	0.00345	0.00433	CcSEcCtD
Diphenhydramine—Urticaria—Topotecan—ovarian cancer	0.00342	0.0043	CcSEcCtD
Diphenhydramine—Urticaria—Melphalan—ovarian cancer	0.00335	0.00421	CcSEcCtD
Diphenhydramine—Diarrhoea—Chlorambucil—ovarian cancer	0.00331	0.00416	CcSEcCtD
Diphenhydramine—Paraesthesia—Vinorelbine—ovarian cancer	0.00331	0.00416	CcSEcCtD
Diphenhydramine—Photosensitivity—Epirubicin—ovarian cancer	0.00329	0.00413	CcSEcCtD
Diphenhydramine—Tinnitus—Paclitaxel—ovarian cancer	0.00325	0.00409	CcSEcCtD
Diphenhydramine—Neuropathy peripheral—Docetaxel—ovarian cancer	0.00323	0.00406	CcSEcCtD
Diphenhydramine—Decreased appetite—Vinorelbine—ovarian cancer	0.00321	0.00403	CcSEcCtD
Diphenhydramine—Fatigue—Vinorelbine—ovarian cancer	0.00318	0.00399	CcSEcCtD
Diphenhydramine—Constipation—Vinorelbine—ovarian cancer	0.00315	0.00396	CcSEcCtD
Diphenhydramine—Chills—Paclitaxel—ovarian cancer	0.00313	0.00393	CcSEcCtD
Diphenhydramine—Asthenia—Topotecan—ovarian cancer	0.00309	0.00388	CcSEcCtD
Diphenhydramine—Vomiting—Chlorambucil—ovarian cancer	0.00308	0.00387	CcSEcCtD
Diphenhydramine—Agranulocytosis—Docetaxel—ovarian cancer	0.00308	0.00386	CcSEcCtD
Diphenhydramine—Clomifene—ESR1—ovarian cancer	0.00306	0.143	CrCbGaD
Diphenhydramine—Photosensitivity—Doxorubicin—ovarian cancer	0.00304	0.00382	CcSEcCtD
Diphenhydramine—Feeling abnormal—Vinorelbine—ovarian cancer	0.00304	0.00382	CcSEcCtD
Diphenhydramine—Asthenia—Melphalan—ovarian cancer	0.00303	0.0038	CcSEcCtD
Diphenhydramine—HRH1—myometrium—ovarian cancer	0.003	0.0335	CbGeAlD
Diphenhydramine—Tension—Paclitaxel—ovarian cancer	0.00298	0.00375	CcSEcCtD
Diphenhydramine—Nervousness—Paclitaxel—ovarian cancer	0.00295	0.00371	CcSEcCtD
Diphenhydramine—Diarrhoea—Topotecan—ovarian cancer	0.00295	0.0037	CcSEcCtD
Diphenhydramine—Urticaria—Vinorelbine—ovarian cancer	0.00293	0.00368	CcSEcCtD
Diphenhydramine—Diarrhoea—Melphalan—ovarian cancer	0.00289	0.00363	CcSEcCtD
Diphenhydramine—Diplopia—Epirubicin—ovarian cancer	0.00288	0.00362	CcSEcCtD
Diphenhydramine—Nausea—Chlorambucil—ovarian cancer	0.00288	0.00361	CcSEcCtD
Diphenhydramine—Vision blurred—Paclitaxel—ovarian cancer	0.00286	0.0036	CcSEcCtD
Diphenhydramine—Dizziness—Topotecan—ovarian cancer	0.00285	0.00358	CcSEcCtD
Diphenhydramine—Tremor—Paclitaxel—ovarian cancer	0.00285	0.00358	CcSEcCtD
Diphenhydramine—Agitation—Paclitaxel—ovarian cancer	0.00279	0.00351	CcSEcCtD
Diphenhydramine—SLC22A5—uterine cervix—ovarian cancer	0.00276	0.0308	CbGeAlD
Diphenhydramine—Vomiting—Topotecan—ovarian cancer	0.00274	0.00344	CcSEcCtD
Diphenhydramine—Vertigo—Paclitaxel—ovarian cancer	0.00273	0.00343	CcSEcCtD
Diphenhydramine—Rash—Topotecan—ovarian cancer	0.00272	0.00341	CcSEcCtD
Diphenhydramine—Dermatitis—Topotecan—ovarian cancer	0.00272	0.00341	CcSEcCtD
Diphenhydramine—Headache—Topotecan—ovarian cancer	0.0027	0.00339	CcSEcCtD
Diphenhydramine—SLC22A1—vagina—ovarian cancer	0.00269	0.03	CbGeAlD
Diphenhydramine—Palpitations—Paclitaxel—ovarian cancer	0.00269	0.00337	CcSEcCtD
Diphenhydramine—Vomiting—Melphalan—ovarian cancer	0.00268	0.00337	CcSEcCtD
Diphenhydramine—Diplopia—Doxorubicin—ovarian cancer	0.00267	0.00335	CcSEcCtD
Diphenhydramine—Rash—Melphalan—ovarian cancer	0.00266	0.00334	CcSEcCtD
Diphenhydramine—Dermatitis—Melphalan—ovarian cancer	0.00266	0.00334	CcSEcCtD
Diphenhydramine—Chills—Docetaxel—ovarian cancer	0.00265	0.00333	CcSEcCtD
Diphenhydramine—Asthenia—Vinorelbine—ovarian cancer	0.00265	0.00332	CcSEcCtD
Diphenhydramine—Convulsion—Paclitaxel—ovarian cancer	0.00263	0.00331	CcSEcCtD
Diphenhydramine—Nausea—Topotecan—ovarian cancer	0.00256	0.00322	CcSEcCtD
Diphenhydramine—Dry mouth—Paclitaxel—ovarian cancer	0.00253	0.00318	CcSEcCtD
Diphenhydramine—Diarrhoea—Vinorelbine—ovarian cancer	0.00252	0.00317	CcSEcCtD
Diphenhydramine—Nausea—Melphalan—ovarian cancer	0.00251	0.00315	CcSEcCtD
Diphenhydramine—Confusional state—Paclitaxel—ovarian cancer	0.0025	0.00314	CcSEcCtD
Diphenhydramine—SLC22A5—endometrium—ovarian cancer	0.00249	0.0278	CbGeAlD
Diphenhydramine—Dizziness—Vinorelbine—ovarian cancer	0.00244	0.00306	CcSEcCtD
Diphenhydramine—Thrombocytopenia—Paclitaxel—ovarian cancer	0.00243	0.00305	CcSEcCtD
Diphenhydramine—Tachycardia—Paclitaxel—ovarian cancer	0.00242	0.00304	CcSEcCtD
Diphenhydramine—Hyperhidrosis—Paclitaxel—ovarian cancer	0.0024	0.00301	CcSEcCtD
Diphenhydramine—Anorexia—Paclitaxel—ovarian cancer	0.00236	0.00297	CcSEcCtD
Diphenhydramine—HRH1—epithelium—ovarian cancer	0.00236	0.0263	CbGeAlD
Diphenhydramine—Vomiting—Vinorelbine—ovarian cancer	0.00234	0.00294	CcSEcCtD
Diphenhydramine—HRH1—uterine cervix—ovarian cancer	0.00234	0.0261	CbGeAlD
Diphenhydramine—Dysuria—Epirubicin—ovarian cancer	0.00233	0.00293	CcSEcCtD
Diphenhydramine—Rash—Vinorelbine—ovarian cancer	0.00232	0.00292	CcSEcCtD
Diphenhydramine—Dermatitis—Vinorelbine—ovarian cancer	0.00232	0.00292	CcSEcCtD
Diphenhydramine—Hypotension—Paclitaxel—ovarian cancer	0.00232	0.00291	CcSEcCtD
Diphenhydramine—Headache—Vinorelbine—ovarian cancer	0.00231	0.0029	CcSEcCtD
Diphenhydramine—Pollakiuria—Epirubicin—ovarian cancer	0.0023	0.00289	CcSEcCtD
Diphenhydramine—Palpitations—Docetaxel—ovarian cancer	0.00228	0.00286	CcSEcCtD
Diphenhydramine—Photosensitivity reaction—Epirubicin—ovarian cancer	0.00228	0.00286	CcSEcCtD
Diphenhydramine—Insomnia—Paclitaxel—ovarian cancer	0.00224	0.00282	CcSEcCtD
Diphenhydramine—Convulsion—Docetaxel—ovarian cancer	0.00223	0.0028	CcSEcCtD
Diphenhydramine—HRH1—decidua—ovarian cancer	0.00223	0.0249	CbGeAlD
Diphenhydramine—Paraesthesia—Paclitaxel—ovarian cancer	0.00223	0.0028	CcSEcCtD
Diphenhydramine—Drowsiness—Epirubicin—ovarian cancer	0.00222	0.00279	CcSEcCtD
Diphenhydramine—Somnolence—Paclitaxel—ovarian cancer	0.0022	0.00277	CcSEcCtD
Diphenhydramine—Nausea—Vinorelbine—ovarian cancer	0.00219	0.00275	CcSEcCtD
Diphenhydramine—PTGS1—epithelium—ovarian cancer	0.00218	0.0244	CbGeAlD
Diphenhydramine—Dyspepsia—Paclitaxel—ovarian cancer	0.00218	0.00274	CcSEcCtD
Diphenhydramine—Neuropathy peripheral—Epirubicin—ovarian cancer	0.00218	0.00274	CcSEcCtD
Diphenhydramine—PTGS1—uterine cervix—ovarian cancer	0.00216	0.0242	CbGeAlD
Diphenhydramine—Dysuria—Doxorubicin—ovarian cancer	0.00216	0.00271	CcSEcCtD
Diphenhydramine—Decreased appetite—Paclitaxel—ovarian cancer	0.00216	0.00271	CcSEcCtD
Diphenhydramine—Dry mouth—Docetaxel—ovarian cancer	0.00214	0.00269	CcSEcCtD
Diphenhydramine—Fatigue—Paclitaxel—ovarian cancer	0.00214	0.00269	CcSEcCtD
Diphenhydramine—Pollakiuria—Doxorubicin—ovarian cancer	0.00213	0.00268	CcSEcCtD
Diphenhydramine—Constipation—Paclitaxel—ovarian cancer	0.00212	0.00266	CcSEcCtD
Diphenhydramine—Confusional state—Docetaxel—ovarian cancer	0.00212	0.00266	CcSEcCtD
Diphenhydramine—HRH1—endometrium—ovarian cancer	0.00211	0.0236	CbGeAlD
Diphenhydramine—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.00211	0.00265	CcSEcCtD
Diphenhydramine—Tamoxifen—CYP1B1—ovarian cancer	0.0021	0.098	CrCbGaD
Diphenhydramine—Agranulocytosis—Epirubicin—ovarian cancer	0.00207	0.00261	CcSEcCtD
Diphenhydramine—CYP2C19—vagina—ovarian cancer	0.00207	0.0231	CbGeAlD
Diphenhydramine—SLC22A5—female reproductive system—ovarian cancer	0.00207	0.0231	CbGeAlD
Diphenhydramine—Thrombocytopenia—Docetaxel—ovarian cancer	0.00206	0.00259	CcSEcCtD
Diphenhydramine—Drowsiness—Doxorubicin—ovarian cancer	0.00206	0.00258	CcSEcCtD
Diphenhydramine—Tachycardia—Docetaxel—ovarian cancer	0.00205	0.00258	CcSEcCtD
Diphenhydramine—Feeling abnormal—Paclitaxel—ovarian cancer	0.00204	0.00257	CcSEcCtD
Diphenhydramine—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.00202	0.00253	CcSEcCtD
Diphenhydramine—CYP2B6—gonad—ovarian cancer	0.00201	0.0224	CbGeAlD
Diphenhydramine—Anorexia—Docetaxel—ovarian cancer	0.002	0.00252	CcSEcCtD
Diphenhydramine—Urticaria—Paclitaxel—ovarian cancer	0.00197	0.00247	CcSEcCtD
Diphenhydramine—Hypotension—Docetaxel—ovarian cancer	0.00196	0.00247	CcSEcCtD
Diphenhydramine—PTGS1—endometrium—ovarian cancer	0.00196	0.0218	CbGeAlD
Diphenhydramine—Agranulocytosis—Doxorubicin—ovarian cancer	0.00192	0.00241	CcSEcCtD
Diphenhydramine—Insomnia—Docetaxel—ovarian cancer	0.0019	0.00239	CcSEcCtD
Diphenhydramine—Reboxetine—ABCB1—ovarian cancer	0.0019	0.0888	CrCbGaD
Diphenhydramine—Paraesthesia—Docetaxel—ovarian cancer	0.00189	0.00237	CcSEcCtD
Diphenhydramine—SLC22A5—female gonad—ovarian cancer	0.00188	0.021	CbGeAlD
Diphenhydramine—Somnolence—Docetaxel—ovarian cancer	0.00187	0.00235	CcSEcCtD
Diphenhydramine—SLC22A5—vagina—ovarian cancer	0.00187	0.0208	CbGeAlD
Diphenhydramine—Tinnitus—Epirubicin—ovarian cancer	0.00186	0.00234	CcSEcCtD
Diphenhydramine—Dyspepsia—Docetaxel—ovarian cancer	0.00185	0.00232	CcSEcCtD
Diphenhydramine—Decreased appetite—Docetaxel—ovarian cancer	0.00183	0.0023	CcSEcCtD
Diphenhydramine—Fatigue—Docetaxel—ovarian cancer	0.00181	0.00228	CcSEcCtD
Diphenhydramine—PTGS1—uterus—ovarian cancer	0.0018	0.0201	CbGeAlD
Diphenhydramine—Constipation—Docetaxel—ovarian cancer	0.0018	0.00226	CcSEcCtD
Diphenhydramine—CYP2B6—female reproductive system—ovarian cancer	0.00179	0.02	CbGeAlD
Diphenhydramine—Chills—Epirubicin—ovarian cancer	0.00179	0.00225	CcSEcCtD
Diphenhydramine—Asthenia—Paclitaxel—ovarian cancer	0.00178	0.00224	CcSEcCtD
Diphenhydramine—CYP2C9—female reproductive system—ovarian cancer	0.00178	0.0198	CbGeAlD
Diphenhydramine—HRH1—female reproductive system—ovarian cancer	0.00175	0.0195	CbGeAlD
Diphenhydramine—Feeling abnormal—Docetaxel—ovarian cancer	0.00173	0.00218	CcSEcCtD
Diphenhydramine—Tinnitus—Doxorubicin—ovarian cancer	0.00172	0.00216	CcSEcCtD
Diphenhydramine—Tension—Epirubicin—ovarian cancer	0.0017	0.00214	CcSEcCtD
Diphenhydramine—Diarrhoea—Paclitaxel—ovarian cancer	0.0017	0.00213	CcSEcCtD
Diphenhydramine—Nervousness—Epirubicin—ovarian cancer	0.00169	0.00212	CcSEcCtD
Diphenhydramine—SLC22A5—testis—ovarian cancer	0.00167	0.0186	CbGeAlD
Diphenhydramine—Chills—Doxorubicin—ovarian cancer	0.00166	0.00208	CcSEcCtD
Diphenhydramine—Dizziness—Paclitaxel—ovarian cancer	0.00164	0.00206	CcSEcCtD
Diphenhydramine—Vision blurred—Epirubicin—ovarian cancer	0.00164	0.00206	CcSEcCtD
Diphenhydramine—CYP2B6—vagina—ovarian cancer	0.00162	0.0181	CbGeAlD
Diphenhydramine—PTGS1—female reproductive system—ovarian cancer	0.00162	0.0181	CbGeAlD
Diphenhydramine—Agitation—Epirubicin—ovarian cancer	0.0016	0.00201	CcSEcCtD
Diphenhydramine—HRH1—female gonad—ovarian cancer	0.00159	0.0178	CbGeAlD
Diphenhydramine—HRH1—vagina—ovarian cancer	0.00158	0.0177	CbGeAlD
Diphenhydramine—Tension—Doxorubicin—ovarian cancer	0.00158	0.00198	CcSEcCtD
Diphenhydramine—Vomiting—Paclitaxel—ovarian cancer	0.00158	0.00198	CcSEcCtD
Diphenhydramine—Rash—Paclitaxel—ovarian cancer	0.00156	0.00196	CcSEcCtD
Diphenhydramine—Dermatitis—Paclitaxel—ovarian cancer	0.00156	0.00196	CcSEcCtD
Diphenhydramine—Nervousness—Doxorubicin—ovarian cancer	0.00156	0.00196	CcSEcCtD
Diphenhydramine—Vertigo—Epirubicin—ovarian cancer	0.00156	0.00196	CcSEcCtD
Diphenhydramine—Headache—Paclitaxel—ovarian cancer	0.00155	0.00195	CcSEcCtD
Diphenhydramine—Palpitations—Epirubicin—ovarian cancer	0.00154	0.00193	CcSEcCtD
Diphenhydramine—Vision blurred—Doxorubicin—ovarian cancer	0.00151	0.0019	CcSEcCtD
Diphenhydramine—Asthenia—Docetaxel—ovarian cancer	0.00151	0.00189	CcSEcCtD
Diphenhydramine—Toremifene—ABCB1—ovarian cancer	0.00151	0.0704	CrCbGaD
Diphenhydramine—Convulsion—Epirubicin—ovarian cancer	0.00151	0.00189	CcSEcCtD
Diphenhydramine—Agitation—Doxorubicin—ovarian cancer	0.00148	0.00186	CcSEcCtD
Diphenhydramine—PTGS1—female gonad—ovarian cancer	0.00148	0.0165	CbGeAlD
Diphenhydramine—Nausea—Paclitaxel—ovarian cancer	0.00147	0.00185	CcSEcCtD
Diphenhydramine—PTGS1—vagina—ovarian cancer	0.00147	0.0164	CbGeAlD
Diphenhydramine—CYP2B6—testis—ovarian cancer	0.00145	0.0162	CbGeAlD
Diphenhydramine—Dry mouth—Epirubicin—ovarian cancer	0.00145	0.00182	CcSEcCtD
Diphenhydramine—Vertigo—Doxorubicin—ovarian cancer	0.00144	0.00181	CcSEcCtD
Diphenhydramine—Diarrhoea—Docetaxel—ovarian cancer	0.00144	0.00181	CcSEcCtD
Diphenhydramine—Confusional state—Epirubicin—ovarian cancer	0.00143	0.0018	CcSEcCtD
Diphenhydramine—Palpitations—Doxorubicin—ovarian cancer	0.00142	0.00178	CcSEcCtD
Diphenhydramine—Tamoxifen—ESR1—ovarian cancer	0.00142	0.0662	CrCbGaD
Diphenhydramine—HRH1—testis—ovarian cancer	0.00141	0.0158	CbGeAlD
Diphenhydramine—Convulsion—Doxorubicin—ovarian cancer	0.00139	0.00175	CcSEcCtD
Diphenhydramine—Dizziness—Docetaxel—ovarian cancer	0.00139	0.00175	CcSEcCtD
Diphenhydramine—Thrombocytopenia—Epirubicin—ovarian cancer	0.00139	0.00174	CcSEcCtD
Diphenhydramine—Tachycardia—Epirubicin—ovarian cancer	0.00138	0.00174	CcSEcCtD
Diphenhydramine—Hyperhidrosis—Epirubicin—ovarian cancer	0.00137	0.00172	CcSEcCtD
Diphenhydramine—Anorexia—Epirubicin—ovarian cancer	0.00135	0.0017	CcSEcCtD
Diphenhydramine—Dry mouth—Doxorubicin—ovarian cancer	0.00134	0.00168	CcSEcCtD
Diphenhydramine—Vomiting—Docetaxel—ovarian cancer	0.00134	0.00168	CcSEcCtD
Diphenhydramine—CYP2D6—female reproductive system—ovarian cancer	0.00133	0.0149	CbGeAlD
Diphenhydramine—Rash—Docetaxel—ovarian cancer	0.00133	0.00166	CcSEcCtD
Diphenhydramine—Hypotension—Epirubicin—ovarian cancer	0.00132	0.00166	CcSEcCtD
Diphenhydramine—Dermatitis—Docetaxel—ovarian cancer	0.00132	0.00166	CcSEcCtD
Diphenhydramine—Confusional state—Doxorubicin—ovarian cancer	0.00132	0.00166	CcSEcCtD
Diphenhydramine—Headache—Docetaxel—ovarian cancer	0.00132	0.00165	CcSEcCtD
Diphenhydramine—PTGS1—testis—ovarian cancer	0.00131	0.0146	CbGeAlD
Diphenhydramine—Clomifene—ABCB1—ovarian cancer	0.0013	0.0609	CrCbGaD
Diphenhydramine—Thrombocytopenia—Doxorubicin—ovarian cancer	0.00128	0.00161	CcSEcCtD
Diphenhydramine—Insomnia—Epirubicin—ovarian cancer	0.00128	0.00161	CcSEcCtD
Diphenhydramine—Tachycardia—Doxorubicin—ovarian cancer	0.00128	0.00161	CcSEcCtD
Diphenhydramine—Paraesthesia—Epirubicin—ovarian cancer	0.00127	0.0016	CcSEcCtD
Diphenhydramine—Hyperhidrosis—Doxorubicin—ovarian cancer	0.00127	0.00159	CcSEcCtD
Diphenhydramine—Somnolence—Epirubicin—ovarian cancer	0.00126	0.00158	CcSEcCtD
Diphenhydramine—Anorexia—Doxorubicin—ovarian cancer	0.00125	0.00157	CcSEcCtD
Diphenhydramine—Nausea—Docetaxel—ovarian cancer	0.00125	0.00157	CcSEcCtD
Diphenhydramine—Dyspepsia—Epirubicin—ovarian cancer	0.00125	0.00157	CcSEcCtD
Diphenhydramine—Decreased appetite—Epirubicin—ovarian cancer	0.00123	0.00155	CcSEcCtD
Diphenhydramine—Hypotension—Doxorubicin—ovarian cancer	0.00123	0.00154	CcSEcCtD
Diphenhydramine—Fatigue—Epirubicin—ovarian cancer	0.00122	0.00154	CcSEcCtD
Diphenhydramine—CYP2D6—female gonad—ovarian cancer	0.00121	0.0135	CbGeAlD
Diphenhydramine—Constipation—Epirubicin—ovarian cancer	0.00121	0.00152	CcSEcCtD
Diphenhydramine—SLC22A5—lymph node—ovarian cancer	0.00121	0.0135	CbGeAlD
Diphenhydramine—Insomnia—Doxorubicin—ovarian cancer	0.00119	0.00149	CcSEcCtD
Diphenhydramine—Paraesthesia—Doxorubicin—ovarian cancer	0.00118	0.00148	CcSEcCtD
Diphenhydramine—Feeling abnormal—Epirubicin—ovarian cancer	0.00117	0.00147	CcSEcCtD
Diphenhydramine—Somnolence—Doxorubicin—ovarian cancer	0.00117	0.00147	CcSEcCtD
Diphenhydramine—Dyspepsia—Doxorubicin—ovarian cancer	0.00115	0.00145	CcSEcCtD
Diphenhydramine—Decreased appetite—Doxorubicin—ovarian cancer	0.00114	0.00143	CcSEcCtD
Diphenhydramine—Fatigue—Doxorubicin—ovarian cancer	0.00113	0.00142	CcSEcCtD
Diphenhydramine—Urticaria—Epirubicin—ovarian cancer	0.00113	0.00141	CcSEcCtD
Diphenhydramine—Constipation—Doxorubicin—ovarian cancer	0.00112	0.00141	CcSEcCtD
Diphenhydramine—Feeling abnormal—Doxorubicin—ovarian cancer	0.00108	0.00136	CcSEcCtD
Diphenhydramine—CYP2D6—testis—ovarian cancer	0.00108	0.012	CbGeAlD
Diphenhydramine—Urticaria—Doxorubicin—ovarian cancer	0.00104	0.00131	CcSEcCtD
Diphenhydramine—HRH1—lymph node—ovarian cancer	0.00102	0.0114	CbGeAlD
Diphenhydramine—Asthenia—Epirubicin—ovarian cancer	0.00102	0.00128	CcSEcCtD
Diphenhydramine—Diarrhoea—Epirubicin—ovarian cancer	0.00097	0.00122	CcSEcCtD
Diphenhydramine—PTGS1—lymph node—ovarian cancer	0.000949	0.0106	CbGeAlD
Diphenhydramine—Bepridil—ABCB1—ovarian cancer	0.000946	0.0442	CrCbGaD
Diphenhydramine—Asthenia—Doxorubicin—ovarian cancer	0.000941	0.00118	CcSEcCtD
Diphenhydramine—Dizziness—Epirubicin—ovarian cancer	0.000938	0.00118	CcSEcCtD
Diphenhydramine—Vomiting—Epirubicin—ovarian cancer	0.000901	0.00113	CcSEcCtD
Diphenhydramine—Diarrhoea—Doxorubicin—ovarian cancer	0.000898	0.00113	CcSEcCtD
Diphenhydramine—Rash—Epirubicin—ovarian cancer	0.000894	0.00112	CcSEcCtD
Diphenhydramine—Dermatitis—Epirubicin—ovarian cancer	0.000893	0.00112	CcSEcCtD
Diphenhydramine—Headache—Epirubicin—ovarian cancer	0.000888	0.00112	CcSEcCtD
Diphenhydramine—Fentanyl—ABCB1—ovarian cancer	0.00087	0.0407	CrCbGaD
Diphenhydramine—Dizziness—Doxorubicin—ovarian cancer	0.000868	0.00109	CcSEcCtD
Diphenhydramine—Nausea—Epirubicin—ovarian cancer	0.000842	0.00106	CcSEcCtD
Diphenhydramine—Vomiting—Doxorubicin—ovarian cancer	0.000834	0.00105	CcSEcCtD
Diphenhydramine—Rash—Doxorubicin—ovarian cancer	0.000827	0.00104	CcSEcCtD
Diphenhydramine—Dermatitis—Doxorubicin—ovarian cancer	0.000826	0.00104	CcSEcCtD
Diphenhydramine—Headache—Doxorubicin—ovarian cancer	0.000822	0.00103	CcSEcCtD
Diphenhydramine—Phenytoin—ABCB1—ovarian cancer	0.000789	0.0369	CrCbGaD
Diphenhydramine—Nausea—Doxorubicin—ovarian cancer	0.000779	0.000979	CcSEcCtD
Diphenhydramine—Trimipramine—ABCB1—ovarian cancer	0.000629	0.0294	CrCbGaD
Diphenhydramine—Promethazine—ABCB1—ovarian cancer	0.000606	0.0283	CrCbGaD
Diphenhydramine—Tamoxifen—ABCB1—ovarian cancer	0.000602	0.0281	CrCbGaD
Diphenhydramine—Doxepin—ABCB1—ovarian cancer	0.0006	0.028	CrCbGaD
Diphenhydramine—Methadone—ABCB1—ovarian cancer	0.000596	0.0279	CrCbGaD
Diphenhydramine—Imipramine—ABCB1—ovarian cancer	0.000467	0.0218	CrCbGaD
Diphenhydramine—Amitriptyline—ABCB1—ovarian cancer	0.000464	0.0217	CrCbGaD
Diphenhydramine—CHRM2—Signaling Pathways—XIAP—ovarian cancer	4.62e-05	0.000497	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—CYP1B1—ovarian cancer	4.57e-05	0.000492	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—SMARCA4—ovarian cancer	4.57e-05	0.000492	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—SMARCA4—ovarian cancer	4.5e-05	0.000484	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—EREG—ovarian cancer	4.46e-05	0.00048	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—EREG—ovarian cancer	4.39e-05	0.000472	CbGpPWpGaD
Diphenhydramine—CYP2C18—Metabolism—PIK3CG—ovarian cancer	4.39e-05	0.000472	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—PPP2R1A—ovarian cancer	4.35e-05	0.000468	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—BRIP1—ovarian cancer	4.3e-05	0.000462	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—PPP1CC—ovarian cancer	4.3e-05	0.000462	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—PPP2R1A—ovarian cancer	4.23e-05	0.000454	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4.2e-05	0.000452	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—PGR—ovarian cancer	4.18e-05	0.00045	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—PGR—ovarian cancer	4.11e-05	0.000443	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—PPP2R1A—ovarian cancer	4.06e-05	0.000436	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—ABCB1—ovarian cancer	4.04e-05	0.000435	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	4.02e-05	0.000432	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—FASN—ovarian cancer	3.99e-05	0.000429	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—TYMS—ovarian cancer	3.97e-05	0.000427	CbGpPWpGaD
Diphenhydramine—HRH1—GPCR downstream signaling—PIK3CG—ovarian cancer	3.93e-05	0.000423	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—SLC5A5—ovarian cancer	3.93e-05	0.000422	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—ABCB1—ovarian cancer	3.92e-05	0.000422	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—PARP1—ovarian cancer	3.89e-05	0.000418	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCR downstream signaling—PIK3CG—ovarian cancer	3.87e-05	0.000416	CbGpPWpGaD
Diphenhydramine—CYP2C18—Metabolism—PIK3CD—ovarian cancer	3.86e-05	0.000415	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—TYMS—ovarian cancer	3.85e-05	0.000414	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—PARP1—ovarian cancer	3.83e-05	0.000411	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—SLC2A1—ovarian cancer	3.79e-05	0.000408	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—ABCB1—ovarian cancer	3.77e-05	0.000405	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—IL6ST—ovarian cancer	3.72e-05	0.0004	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—YAP1—ovarian cancer	3.7e-05	0.000398	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—TYMS—ovarian cancer	3.7e-05	0.000398	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	3.66e-05	0.000394	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	3.66e-05	0.000394	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—IL6ST—ovarian cancer	3.66e-05	0.000394	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—CYP1B1—ovarian cancer	3.63e-05	0.000391	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—PIK3CG—ovarian cancer	3.57e-05	0.000384	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—PIK3CG—ovarian cancer	3.52e-05	0.000378	CbGpPWpGaD
Diphenhydramine—HRH1—GPCR downstream signaling—PIK3CD—ovarian cancer	3.46e-05	0.000372	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCR downstream signaling—PIK3CD—ovarian cancer	3.4e-05	0.000366	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—YAP1—ovarian cancer	3.4e-05	0.000366	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—YAP1—ovarian cancer	3.37e-05	0.000363	CbGpPWpGaD
Diphenhydramine—CYP2C18—Metabolism—PIK3CB—ovarian cancer	3.36e-05	0.000362	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	3.34e-05	0.000359	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—PPP2R1A—ovarian cancer	3.22e-05	0.000347	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	3.22e-05	0.000346	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—CAV1—ovarian cancer	3.2e-05	0.000344	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—PPP2R1A—ovarian cancer	3.15e-05	0.000339	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—PIK3CD—ovarian cancer	3.14e-05	0.000338	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	3.13e-05	0.000337	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—CAV1—ovarian cancer	3.1e-05	0.000334	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—PPP2R1A—ovarian cancer	3.1e-05	0.000334	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—PIK3CD—ovarian cancer	3.09e-05	0.000332	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—FASN—ovarian cancer	3.02e-05	0.000324	CbGpPWpGaD
Diphenhydramine—HRH1—GPCR downstream signaling—PIK3CB—ovarian cancer	3.01e-05	0.000324	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—ABCB1—ovarian cancer	2.99e-05	0.000322	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—CAV1—ovarian cancer	2.98e-05	0.000321	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCR downstream signaling—PIK3CB—ovarian cancer	2.97e-05	0.000319	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—SLC5A5—ovarian cancer	2.97e-05	0.000319	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.97e-05	0.000319	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—TYMS—ovarian cancer	2.94e-05	0.000316	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.93e-05	0.000316	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—PIK3CG—ovarian cancer	2.91e-05	0.000313	CbGpPWpGaD
Diphenhydramine—CYP2C18—Metabolism—PTEN—ovarian cancer	2.91e-05	0.000313	CbGpPWpGaD
Diphenhydramine—HRH1—GPCR downstream signaling—CXCL8—ovarian cancer	2.9e-05	0.000312	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—YAP1—ovarian cancer	2.88e-05	0.00031	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—SLC2A1—ovarian cancer	2.86e-05	0.000308	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.85e-05	0.000307	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCR downstream signaling—CXCL8—ovarian cancer	2.85e-05	0.000307	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—PIK3CG—ovarian cancer	2.83e-05	0.000304	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.81e-05	0.000302	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—FASN—ovarian cancer	2.77e-05	0.000298	CbGpPWpGaD
Diphenhydramine—HRH1—GPCR downstream signaling—IL2—ovarian cancer	2.77e-05	0.000298	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—FASN—ovarian cancer	2.75e-05	0.000296	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—CYP1B1—ovarian cancer	2.75e-05	0.000295	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—PIK3CB—ovarian cancer	2.74e-05	0.000294	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—SLC5A5—ovarian cancer	2.73e-05	0.000293	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCR downstream signaling—IL2—ovarian cancer	2.72e-05	0.000293	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—PIK3CG—ovarian cancer	2.72e-05	0.000292	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—SLC5A5—ovarian cancer	2.7e-05	0.000291	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—PIK3CB—ovarian cancer	2.69e-05	0.00029	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—SLC2A1—ovarian cancer	2.64e-05	0.000283	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—CXCL8—ovarian cancer	2.63e-05	0.000283	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—SLC2A1—ovarian cancer	2.61e-05	0.000281	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—CXCL8—ovarian cancer	2.59e-05	0.000278	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—PIK3CD—ovarian cancer	2.56e-05	0.000275	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.56e-05	0.000275	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—CYP1B1—ovarian cancer	2.53e-05	0.000272	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—IL2—ovarian cancer	2.51e-05	0.00027	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.51e-05	0.00027	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—TERT—ovarian cancer	2.51e-05	0.000269	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—CYP1B1—ovarian cancer	2.5e-05	0.000269	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—PIK3CD—ovarian cancer	2.49e-05	0.000267	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—IL2—ovarian cancer	2.47e-05	0.000266	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—TERT—ovarian cancer	2.46e-05	0.000265	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	2.44e-05	0.000262	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.42e-05	0.000261	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—PIK3CD—ovarian cancer	2.39e-05	0.000257	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—CAV1—ovarian cancer	2.37e-05	0.000255	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—FASN—ovarian cancer	2.35e-05	0.000253	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—CAV1—ovarian cancer	2.32e-05	0.000249	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—SLC5A5—ovarian cancer	2.31e-05	0.000249	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—CAV1—ovarian cancer	2.28e-05	0.000245	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—ABCB1—ovarian cancer	2.26e-05	0.000243	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	2.24e-05	0.000241	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—ESR1—ovarian cancer	2.23e-05	0.00024	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—SLC2A1—ovarian cancer	2.23e-05	0.00024	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—PIK3CB—ovarian cancer	2.23e-05	0.00024	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—TYMS—ovarian cancer	2.22e-05	0.000239	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	2.22e-05	0.000239	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.21e-05	0.000238	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—ESR1—ovarian cancer	2.2e-05	0.000236	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—IL6ST—ovarian cancer	2.2e-05	0.000236	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.19e-05	0.000235	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—PIK3CB—ovarian cancer	2.17e-05	0.000233	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—IL6ST—ovarian cancer	2.16e-05	0.000232	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—PIK3CG—ovarian cancer	2.16e-05	0.000232	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—CYP1B1—ovarian cancer	2.14e-05	0.00023	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—APC—ovarian cancer	2.11e-05	0.000227	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—PIK3CG—ovarian cancer	2.11e-05	0.000227	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—NRAS—ovarian cancer	2.11e-05	0.000227	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—PIK3CB—ovarian cancer	2.08e-05	0.000224	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—ABCB1—ovarian cancer	2.08e-05	0.000224	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—APC—ovarian cancer	2.08e-05	0.000223	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—PIK3CG—ovarian cancer	2.08e-05	0.000223	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—NRAS—ovarian cancer	2.08e-05	0.000223	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—ABCB1—ovarian cancer	2.06e-05	0.000222	CbGpPWpGaD
Diphenhydramine—CYP2C18—Metabolism—PIK3CA—ovarian cancer	2.05e-05	0.00022	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—TYMS—ovarian cancer	2.04e-05	0.00022	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—TYMS—ovarian cancer	2.03e-05	0.000218	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—MAPK3—ovarian cancer	2.02e-05	0.000217	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—MAPK3—ovarian cancer	1.99e-05	0.000214	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—PTEN—ovarian cancer	1.93e-05	0.000207	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—MAPK1—ovarian cancer	1.92e-05	0.000207	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—EGFR—ovarian cancer	1.92e-05	0.000207	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	1.9e-05	0.000204	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—PIK3CD—ovarian cancer	1.9e-05	0.000204	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—MAPK1—ovarian cancer	1.89e-05	0.000204	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—EGFR—ovarian cancer	1.89e-05	0.000204	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.89e-05	0.000203	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—PTEN—ovarian cancer	1.87e-05	0.000201	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—PIK3CD—ovarian cancer	1.86e-05	0.0002	CbGpPWpGaD
Diphenhydramine—HRH1—GPCR downstream signaling—PIK3CA—ovarian cancer	1.84e-05	0.000198	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—PIK3CD—ovarian cancer	1.83e-05	0.000196	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—KRAS—ovarian cancer	1.82e-05	0.000195	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCR downstream signaling—PIK3CA—ovarian cancer	1.81e-05	0.000195	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—PTEN—ovarian cancer	1.8e-05	0.000193	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—CAV1—ovarian cancer	1.79e-05	0.000193	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—KRAS—ovarian cancer	1.79e-05	0.000192	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—ABCB1—ovarian cancer	1.76e-05	0.00019	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—TYMS—ovarian cancer	1.73e-05	0.000186	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.71e-05	0.000184	CbGpPWpGaD
Diphenhydramine—CYP2C18—Metabolism—AKT1—ovarian cancer	1.67e-05	0.00018	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—PIK3CA—ovarian cancer	1.67e-05	0.00018	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—PIK3CB—ovarian cancer	1.65e-05	0.000178	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—CAV1—ovarian cancer	1.65e-05	0.000177	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—PIK3CA—ovarian cancer	1.64e-05	0.000177	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—ERBB2—ovarian cancer	1.64e-05	0.000176	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—CAV1—ovarian cancer	1.63e-05	0.000176	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—PIK3CG—ovarian cancer	1.63e-05	0.000175	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—PIK3CB—ovarian cancer	1.62e-05	0.000174	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—MTOR—ovarian cancer	1.62e-05	0.000174	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—ERBB2—ovarian cancer	1.61e-05	0.000173	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—MTOR—ovarian cancer	1.59e-05	0.000171	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—PIK3CB—ovarian cancer	1.59e-05	0.000171	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.56e-05	0.000168	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—CXCL8—ovarian cancer	1.55e-05	0.000167	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—HRAS—ovarian cancer	1.54e-05	0.000166	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—CXCL8—ovarian cancer	1.53e-05	0.000164	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—HRAS—ovarian cancer	1.52e-05	0.000163	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—CDKN1B—ovarian cancer	1.52e-05	0.000163	CbGpPWpGaD
Diphenhydramine—HRH1—GPCR downstream signaling—AKT1—ovarian cancer	1.5e-05	0.000161	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—PIK3CG—ovarian cancer	1.5e-05	0.000161	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—CDKN1B—ovarian cancer	1.49e-05	0.000161	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—CASP3—ovarian cancer	1.49e-05	0.00016	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—PIK3CG—ovarian cancer	1.49e-05	0.00016	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—IL2—ovarian cancer	1.49e-05	0.00016	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—IL6—ovarian cancer	1.48e-05	0.000159	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCR downstream signaling—AKT1—ovarian cancer	1.48e-05	0.000159	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—CASP3—ovarian cancer	1.46e-05	0.000157	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—IL2—ovarian cancer	1.46e-05	0.000157	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—IL6—ovarian cancer	1.45e-05	0.000156	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—CCND1—ovarian cancer	1.45e-05	0.000156	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—CTNNB1—ovarian cancer	1.43e-05	0.000154	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—PIK3CD—ovarian cancer	1.43e-05	0.000154	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—PTEN—ovarian cancer	1.43e-05	0.000154	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—CCND1—ovarian cancer	1.42e-05	0.000153	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—CTNNB1—ovarian cancer	1.41e-05	0.000152	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—MMP9—ovarian cancer	1.41e-05	0.000151	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—PTEN—ovarian cancer	1.4e-05	0.00015	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—CAV1—ovarian cancer	1.39e-05	0.00015	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—MMP9—ovarian cancer	1.38e-05	0.000149	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—PTEN—ovarian cancer	1.38e-05	0.000148	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—AKT1—ovarian cancer	1.36e-05	0.000147	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—PIK3CA—ovarian cancer	1.36e-05	0.000146	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—AKT1—ovarian cancer	1.34e-05	0.000144	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.33e-05	0.000143	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—PIK3CA—ovarian cancer	1.32e-05	0.000142	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—PIK3CD—ovarian cancer	1.32e-05	0.000142	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—PIK3CD—ovarian cancer	1.31e-05	0.000141	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—PIK3CG—ovarian cancer	1.27e-05	0.000137	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—PIK3CA—ovarian cancer	1.27e-05	0.000136	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—VEGFA—ovarian cancer	1.26e-05	0.000136	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—STAT3—ovarian cancer	1.25e-05	0.000134	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—PIK3CB—ovarian cancer	1.25e-05	0.000134	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—NRAS—ovarian cancer	1.25e-05	0.000134	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—VEGFA—ovarian cancer	1.24e-05	0.000134	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—STAT3—ovarian cancer	1.23e-05	0.000132	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—NRAS—ovarian cancer	1.23e-05	0.000132	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—MAPK3—ovarian cancer	1.19e-05	0.000128	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—MAPK3—ovarian cancer	1.17e-05	0.000126	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—MYC—ovarian cancer	1.16e-05	0.000125	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—PIK3CB—ovarian cancer	1.15e-05	0.000124	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—MYC—ovarian cancer	1.14e-05	0.000123	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—PIK3CB—ovarian cancer	1.14e-05	0.000123	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—MAPK1—ovarian cancer	1.14e-05	0.000122	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—EGFR—ovarian cancer	1.14e-05	0.000122	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—MAPK1—ovarian cancer	1.12e-05	0.00012	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—EGFR—ovarian cancer	1.12e-05	0.00012	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—PIK3CD—ovarian cancer	1.12e-05	0.00012	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—AKT1—ovarian cancer	1.11e-05	0.00012	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—PTEN—ovarian cancer	1.08e-05	0.000116	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—AKT1—ovarian cancer	1.08e-05	0.000116	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—KRAS—ovarian cancer	1.07e-05	0.000115	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—KRAS—ovarian cancer	1.06e-05	0.000114	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—AKT1—ovarian cancer	1.04e-05	0.000111	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—PIK3CA—ovarian cancer	1.01e-05	0.000108	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—PTEN—ovarian cancer	9.93e-06	0.000107	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—PIK3CA—ovarian cancer	9.86e-06	0.000106	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—PTEN—ovarian cancer	9.84e-06	0.000106	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—PIK3CB—ovarian cancer	9.73e-06	0.000105	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—PIK3CA—ovarian cancer	9.7e-06	0.000104	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—TP53—ovarian cancer	9.54e-06	0.000103	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—TP53—ovarian cancer	9.38e-06	0.000101	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—HRAS—ovarian cancer	9.12e-06	9.81e-05	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—HRAS—ovarian cancer	8.98e-06	9.65e-05	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—IL6—ovarian cancer	8.73e-06	9.39e-05	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—IL6—ovarian cancer	8.59e-06	9.24e-05	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—PTEN—ovarian cancer	8.41e-06	9.05e-05	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—AKT1—ovarian cancer	8.23e-06	8.86e-05	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—AKT1—ovarian cancer	8.05e-06	8.66e-05	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—AKT1—ovarian cancer	7.92e-06	8.52e-05	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—PIK3CA—ovarian cancer	7.62e-06	8.19e-05	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—PIK3CA—ovarian cancer	7.01e-06	7.53e-05	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—PIK3CA—ovarian cancer	6.94e-06	7.47e-05	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—AKT1—ovarian cancer	6.22e-06	6.69e-05	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—PIK3CA—ovarian cancer	5.93e-06	6.38e-05	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—AKT1—ovarian cancer	5.72e-06	6.16e-05	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—AKT1—ovarian cancer	5.67e-06	6.1e-05	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—AKT1—ovarian cancer	4.85e-06	5.21e-05	CbGpPWpGaD
